Compare Blue Owl Capital Inc. Class A Common Stock (OWL) vs Revolution Medicines Inc. Common Stock (RVMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blue Owl Capital Inc. Class A Common Stock vs Revolution Medicines Inc. Common Stock — how do they compare? Blue Owl Capital Inc. Class A Common Stock trades at $8.81 (market cap $6.35B), while Revolution Medicines Inc. Common Stock trades at $193.15 (market cap $40.39B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 6.4× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays a 9.8% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Blue Owl Capital Inc. Class A Common Stock for 0 Days and Revolution Medicines Inc. Common Stock for 2 Days on average.
| OWL | RVMD | |
|---|---|---|
Market Cap | $6.35B | $40.39B |
Volume | 15,716,423 | 2,941,009 |
Sector | Financials | Health |
52-Week High | $17.17 | $221.15 |
52-Week Low | $8.23 | $49.56 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $10.53B | $37.09B |
Dividend Yield | 9.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Revolution Medicines (RVMD) trades at $188.44, down 2.84% on the day, amid a bearish technical signal. The company reported no revenue in 2025, with a net loss of $1.13 billion, and has missed earnings expectations for three consecutive quarters. However, recent positive developments include the start of a Phase 3 trial for RASONQUE in pancreatic cancer and FDA Breakthrough Therapy Designation, fueling analyst optimism.
The outlook balances high-risk, high-reward potential. Strong analyst support (91.67% buy ratings) and a $253.35 consensus price target suggest significant upside, driven by the promising oncology pipeline. Key risks include substantial cash burn, lack of current revenue, and clinical trial execution uncertainties, making the stock suitable for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →
